Clinical Trial Detail

NCT ID NCT03412799
Title Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sun BioPharma Inc
Indications

pancreatic ductal adenocarcinoma

pancreatic acinar cell adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel + SBP-101

Age Groups: adult senior

No variant requirements are available.